<DOC>
	<DOC>NCT00674141</DOC>
	<brief_summary>The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients</brief_summary>
	<brief_title>Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>MS patients with esatblished relapsing remitting attacks increase in EDSS of at least 1 point for a least one day children under 18 pregnant patients patients with diabetes known allergy to steroids patients who received steroids within 3 months prior to the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Multiple Sclerosis, relapsing remitting, Dexamethasone</keyword>
</DOC>